Venous Thromboembolism Treatment with Enoxaparin

Standard Dosing Regimen

The National Comprehensive Cancer Network recommends enoxaparin for the immediate treatment of VTE at a dose of 1.0 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily 1, 2
Enoxaparin has been shown to be equivalent to unfractionated heparin in terms of symptomatic VTE recurrence and major hemorrhage, with rates of 2.9% and 4.4% vs 4.1% and 1.3% and 1.7% vs 2.1%, respectively 2
For patients with cancer, enoxaparin has shown efficacy compared to warfarin with lower rates of combined outcomes including major bleeding or recurrent VTE, 10.5% vs 21.1% 2

For patients with severe renal insufficiency, the recommended dose is 1 mg/kg subcutaneously every 24 hours, as enoxaparin is associated with a 2-3 fold increased risk of bleeding when administered in standard doses 3, 2
Renal clearance of enoxaparin is reduced by 31% in moderate renal impairment and 44% in severe renal impairment, supporting the need for dose adjustments 3

For patients with BMI ≥40 kg/m², a specific dosing recommendation is available for enoxaparin, with a randomized controlled trial showing similar achievement of goal anti-Xa levels with enoxaparin 1 mg/kg versus 0.8 mg/kg every 12 hours 2

The European Society for Medical Oncology clinical recommendations suggest using 75-80% of the initial dose for extended anticoagulation therapy with enoxaparin 2
In cancer patients, enoxaparin has been shown to be a safe and effective option either alone or in combination with warfarin for extended treatment 2

Low-molecular-weight heparins like enoxaparin significantly reduce VTE incidence compared to vitamin K antagonists in cancer patients, with a relative risk of 0.58 and 95% CI of 0.43-0.77 2
Direct oral anticoagulants like apixaban and rivaroxaban have shown non-inferiority to enoxaparin/warfarin in preventing recurrent VTE, but limited data exists specifically in cancer patients 4

Routine monitoring of anti-Xa levels is not required for most patients on enoxaparin, but may be beneficial in special populations such as patients with severe renal impairment or extreme obesity 3, 2
Peak anti-Xa levels should be measured 4-6 hours after dosing, and only after the patient has received 3-4 doses 3

Failure to adjust dosing in renal impairment can lead to increased bleeding risk, with enoxaparin associated with a 2-3 fold increased risk of bleeding when administered in standard doses to patients with severe renal insufficiency 3, 2
Extended treatment beyond the initial period without appropriate dose reduction may increase bleeding risk, with the European Society for Medical Oncology recommending dose reduction to 75-80% of the initial dose for extended anticoagulation therapy 1, 2